| Literature DB >> 30894788 |
Christina M Meade1, Martina Badell2,3, Stephanie Hackett4, C Christina Mehta5, Lisa B Haddad2,6, Andres Camacho-Gonzalez4,7, Joy Ford4, Marcia M Holstad8, Wendy S Armstrong2,9, Anandi N Sheth2,9.
Abstract
Introduction: While increased healthcare engagement and antiretroviral therapy (ART) adherence occurs during pregnancy, women living with HIV (WLWH) are often lost to follow-up after delivery. We sought to evaluate postpartum retention in care and viral suppression and to identify associated factors among WLWH in a large public hospital in Atlanta, Georgia.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30894788 PMCID: PMC6393891 DOI: 10.1155/2019/8161495
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Demographic and clinical characteristics of WLWH in Atlanta, GA (n=207)1.
|
| N (%) except as noted |
|---|---|
| Age, (years), mean ± SD | 28.1 ± 6.2 |
|
| |
| Race/ethnicity | |
| White (non-Hispanic) | 11 (5.3%) |
| African-American (non-Hispanic) | 162 (78.3%) |
| Hispanic | 14 (6.8%) |
| Other | 20 (9.6%) |
|
| |
| Year of delivery | |
| 2011-2012 | 83 (40.1%) |
| 2013-2014 | 71 (34.3%) |
| 2015-2106 | 53 (25.6%) |
|
| |
| HIV Transmission Risk Factor | |
| Sexual | 122 (58.9%) |
| Perinatal | 22 (10.6%) |
| Other (IVDU, iatrogenic) | 5 (2.4%) |
| Unknown | 58 (28.0%) |
|
| |
| HIV diagnosis during pregnancy | 47 (22.7%) |
|
| |
| Time since HIV diagnosis (years), median (Q1, Q3) | 3 (1, 8) |
|
| |
| In HIV care prior to pregnancy | 114 (55.3%) |
|
| |
| On ART prior to pregnancy | 74 (36.8%) |
|
| |
| Number of previous live births, median (Q1, Q3) | 1 (0, 2) |
|
| |
| Number of prenatal care visits, median (Q1, Q3) | 9 (6, 11) |
|
| |
| CD4 cell count at presentation (cells/mm3), mean ± SD | 412.9 ± 264.4 |
|
| |
| Viral Loads | |
| Viral load <1000 c/mL during entire pregnancy | 85 (42.1%) |
| Viral load <200 c/mL during entire pregnancy | 62 (30.7%) |
| Viral load <1000 c/mL in third trimester | 150 (75.8%) |
| Viral load <200 c/mL in third trimester | 127 (64.1%) |
| Viral load <200 c/mL at delivery | 147 (71.0%) |
|
| |
| ART interruption during pregnancy | 133 (64.9%) |
|
| |
| Cesarean delivery | 99 (48.1%) |
|
| |
| Perinatal HIV infection | 3 (1.5%) |
|
| |
| Contraceptive plan at delivery (mutually exclusive)1 | |
| Tubal Ligation | 20 (9.8%) |
| Hormonal intrauterine device | 17 (8.3%) |
| Copper intrauterine device | 4 (2.0%) |
| Implant | 30 (14.6%) |
| DMPA | 62 (30.2%) |
| Oral contraceptives | 19 (9.3%) |
| Hormonal patch or ring | 3 (1.5%) |
| Condoms alone | 20 (9.8%) |
| None | 15 (7.3%) |
|
| |
| Contraceptive provided at time of delivery | 126 (62.1%) |
|
| |
| Attended 6 week obstetric postpartum appointment | 156 (76.4%) |
|
| |
| Subsequent pregnancy | 44 (23.5%) |
|
| |
| Postpartum transition to HIV Care | |
| Time (days), median (Q1, Q3) | 124 (70, 357) |
| <90 days | 73 (37.1%) |
| 90-180 days | 54 (27.4%) |
| > 180 days | 70 (35.5%) |
| No postpartum HIV visit | 10 (4.8%) |
|
| |
| ART interruption after delivery | 97 (64.2%) |
|
| |
| Change in ART regimen postpartum | 90 (59.2%) |
|
| |
| Viral suppression2 | |
| 12 months postpartum | 76 (41.3%) |
| 24 months postpartum | 46 (30.1%) |
|
| |
| Retention in HIV care2 | |
| 12 months postpartum | 86 (46.5%) |
| 24 months postpartum | 52 (34.0%) |
Abbreviations. IVDU: intravenous drug use; DMPA: Depo Medroxyprogesterone acetate; IUD: intrauterine device.
1 Some women with a contraceptive plan did not receive planned contraception at the time of delivery.
2 Changes in denominator occurred because only 185 women were least 12 months postpartum, and only 153 of the women were at least 24 months postpartum, at the time of analysis.
Figure 1HIV and obstetric care continuum during pregnancy and two years postpartum for 207 HIV infected women. Abbreviations. VS: viral suppression; OB: obstetric.
Multivariable logistic regression models for factors associated with postpartum HIV care retention and viral suppression among WLWH delivering in Atlanta, Georgia, 2011-2016 (n=207).
| Predictor variable | Adjusted Odds Ratio (95% Confidence Interval) | |||
|---|---|---|---|---|
| Retention at 12 months | Retention at 24 months | Viral suppression at 12 months | Viral suppression at 24 months | |
| Year of delivery | 1.13 (087-1.46) | 1.42 (0.96-2.10) | 0.92 (0.71-1.20) | 0.87 (0.58-1.28) |
|
| ||||
| Age in years |
| 1.06 (0.98-1.15) | 1.05 (0.98-1.13) |
|
|
| ||||
| Number of previous live births |
|
| 0.88 (0.68-1.15) | 0.82 (0.60-1.12) |
|
| ||||
| Perinatal HIV infection | 0.31 (0.08-1.19) | 0.36 (0.06-2.05) | 0.32 (0.08-1.15) | ND |
|
| ||||
| Number of prenatal care visits | 1.06 (0.96-1.17) | 1.11 (0.98-1.25) | 1.05 (0.94-1.16) | 1.12 (0.99-1.26) |
|
| ||||
| On ART at pregnancy diagnosis | 1.21 (0.58-2.52) | 1.12 (0.48-2.63) |
| 1.58 (0.69-3.65) |
|
| ||||
| Viral suppression at delivery | 0.81 (0.35-1.85) | 1.17 (0.42-3.25) |
| 2.24 (0.71-7.11) |
|
| ||||
| Attended postpartum obstetric visit | 1.82 (0.78-4.26) | 1.54 (0.51-4.62) | 1.54 (0.62-3.82) | 1.12 (0.38-3.35) |
|
| ||||
| Attended HIV care visit within 90 days of delivery |
|
|
| 2.26 (0.96-5.35) |
Abbreviations. ND: not determined due to small number of observations.
∗ Separate models performed for each outcome. Covariates reported in the existing postpartum HIV care literature were initially included in each model. Covariates which were not predictive of any of the key outcomes in bivariate or initial multivariable analyses (p>0.05) were sequentially removed and excluded from the final model if removal did not alter associations with other variables.